|Bid||90.18 x 1200|
|Ask||260.00 x 900|
|Day's range||220.23 - 226.43|
|52-week range||203.37 - 460.21|
|Beta (5Y monthly)||1.27|
|PE ratio (TTM)||27.58|
|Earnings date||02 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||327.64|
WILMINGTON, Mass. & GHENT, Belgium, June 23, 2022--Charles River and Ziphius Vaccines collaborate to deliver early-stage clinical supply of plasmid DNA for saRNA-based vaccine program.
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.